BJDX vs PATH · rev $249.0K vs P/E 19, rev $1.61B
Bluejay Diagnostics Inc (BJDX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Bluejay Diagnostics Inc (BJDX) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported BJDX revenue for 2022-12-31 was $249.0K. Net income was -$9.3M. BJDX currently screens at market cap $5.0M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
BJDX currently screens at market cap $5.0M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the BJDX and PATH stock pages for the full models.
Not investment advice.